Eli Lilly & Co. - LLY STOCK NEWS

Eli Lilly and Company and Incyte announced positive top-line results from the BRAVE-AA2 Phase 3 trial for baricitinib in treating severe alopecia areata (AA). Both 2-mg and 4-mg doses showed statistically significant scalp hair regrowth at Week 36 compared to placebo. Baricitinib, designated as Breakthrough Therapy by the FDA, aims to address the unmet needs of AA patients, with no current FDA-approved treatments available. The trial involved 546 diverse participants, with no reported severe adverse events. Detailed results will be presented at upcoming conferences.

The U.S. government has purchased a minimum of 100,000 doses of bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) from Eli Lilly for $210 million to treat mild to moderate COVID-19 in high-risk patients. This follows their emergency use authorization for such treatments. Additional doses may be purchased, totaling up to 1,200,000 units under certain conditions. The NIH recommends these antibodies to help reduce severe COVID-19 cases. The purchase is part of Lilly's ongoing efforts to combat COVID-19 with their neutralizing antibodies.

Welldoc and Eli Lilly have announced a collaboration to integrate Welldoc's BlueStar software into Lilly's connected insulin solutions. This partnership aims to develop an updated version of the BlueStar app, which will include insulin dosing data from multiple Lilly insulins. The app, FDA-cleared for diabetes management, supports insulin titration and integrates monitoring tools. Lilly plans to submit regulatory approvals in 2021 and commercialize the platform in the U.S. This collaboration seeks to enhance diabetes care through innovative technology.

Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41^st Annual Health Care Conference on March 4, 2021, at 9:10 a.m. Eastern Time. Chief Scientific Officer Daniel Skovronsky will engage in a fireside chat during the event. Investors and media can access a live audio webcast through Lilly's Investor website, with a replay available for approximately 90 days post-event. Lilly continues its commitment to healthcare innovation, focusing on developing life-changing medicines for global communities.

Eli Lilly and Rigel Pharmaceuticals have announced a global exclusive license agreement to co-develop Rigel's RIPK1 inhibitor, R552, targeting autoimmune and inflammatory diseases. Lilly will make an upfront payment of $125 million and could pay up to $835 million in milestone payments, plus royalties. R552 has completed Phase 1 trials and will enter Phase 2 trials in 2021. Lilly will lead clinical development and commercialization efforts, while Rigel retains co-commercialization rights in the U.S. This partnership seeks to advance treatments in both immune and CNS disease areas.

Eli Lilly and Company's tirzepatide demonstrated significant reductions in A1C levels and body weight in phase 3 clinical trials SURPASS-3 and SURPASS-5 for adult patients with type 2 diabetes. After 52 weeks and 40 weeks, respectively, significant endpoints were achieved, with the highest dose (15 mg) lowering A1C by up to 2.59% and body weight by 12.9 kg. Up to 62.4% of participants achieved A1C levels below 5.7%. The safety profile was comparable to existing GLP-1 receptor agonists, with gastrointestinal issues being the most frequent side effects. Results will be presented at upcoming scientific sessions.

On February 16, 2021, Eli Lilly and Company (NYSE: LLY) appointed Kimberly H. Johnson to its board of directors. Johnson, currently the executive vice president and COO of Fannie Mae, will contribute her expertise in technology, governance, and global risk management. She holds degrees in Economics from Princeton University and an MBA from Columbia Business School. Her addition is expected to enhance the board's capabilities, particularly in financial strategy and oversight.

Eli Lilly and Company (NYSE:LLY) announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021. Senior Vice President Ilya Yuffa will engage in a fireside chat at 1:40 p.m. ET. A live audio webcast will be accessible on Lilly's investor website, with a replay available for 90 days. Founded over a century ago, Lilly remains committed to producing high-quality medicines and enhancing disease management globally.

The U.S. FDA has granted Emergency Use Authorization (EUA) for Eli Lilly's investigational therapy combining bamlanivimab (700 mg) and etesevimab (1400 mg) for treating mild to moderate COVID-19 in high-risk patients aged 12 and older. Administered together via intravenous infusion, this therapy aims to reduce hospitalization and death risk by 70%, based on Phase 3 data from the BLAZE-1 trial. The EUA allows a significant reduction in infusion times and is part of Lilly's ongoing commitment to combat COVID-19. Manufacturing plans include up to 1 million doses by mid-2021.